MAP Infection-Associated Crohn’s Disease: RedHill Biopharma Shows Drug Potential

MAP Infection-Associated Crohn’s Disease: RedHill Biopharma Shows Drug Potential
RedHill Biopharma announced the publication of a peer-review article demonstrating the potential efficacy of RHB-104 for the treatment of Mycobacterium avium subspecies paratuberculosis (MAP) infection-associated Crohn’s disease. The article was authored by researchers from the Burnett School of Biomedical Sciences at the University of Central Florida (UCF) College of Medicine and titled “RHB-104 triple antibiotics combination in culture is bactericidal and should be effective for treatment of Crohn's disease associated with Mycobacterium paratuberculosis
Subscribe or to access all post and page content.